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Cell-based therapies must achieve clinical efficacy and safety with reproducible and cost-effective man-
ufacturing. This study addresses process development issues using the exemplar of a human pluripotent
stem cell-based dopaminergic neuron cell therapy product. Early identification and correction of risks to
product safety and the manufacturing process reduces the expensive and time-consuming bridging stud-
ies later in development. A New Product Introduction map was used to determine the developmental
requirements specific to the product. Systematic Risk Analysis is exemplified here. Expected current value-
based prioritization guides decisions about the sequence of process studies and whether and if an early
abandonment of further research is appropriate. The application of the three tools enabled prioritization
of the development studies.
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Introduction: a developmental dilemma
Regenerative medicine offers hope for many diseases [1]. Such complex products present significant translational
challenges. The development of advanced therapy medicinal products (ATMPs), specifically cell-based medicinal
products (CBMPs), has several features that are largely absent from processes for noncellular medicines:
• The sector containsmany young companies who need revenue early. Theymust avoid long development timelines
and placing large volumes of capital at risk
• The starting and raw materials can be highly variable
• The processes may need ‘hold steps’ in order to be manageable
• The process is often based upon largely manual operations derived from research activity
Many products are being developed in academia and the pressure to obtain clinical results can result in a gap in
process and product understanding [2]. A process change late in development may result in expensive bridging
studies, delaying launch and introducing the risk that the product from the revised process may not perform
adequately. Successful decisions in CBMP development are therefore early decisions [3]. However, until the efficacy
of the product is known from clinical trials the developers cannot know whether such early investment will pay
off. Effective, quantitative decision-making tools are needed. In this paper we consider three tools that we have
applied. We demonstrate the techniques using the manufacture of neural progenitor cells from pluripotent stem
cells (PSCs). The study arises from the UK Regenerative Medicine Platform program (see acknowledgments).
For clarity we have ignored many small decisions, concentrating instead on two big decisions that must be
addressed in process development. Firstly, this process needed at least one ‘hold step,’ in other words, a pause from
which multiple manufacturing campaigns can be managed. We refer to this as the ‘hold step question.’ Secondly,
we prioritized the garnering of efficacy data versus fixing process design for full-scale. We refer to this as the
‘development dilemma’. The two choices are illustrated in Figures 1 & 2 .
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Figure 1. The ‘hold step’ question. This figure describes a hypothetical product development scenario with
representative potential options that can be applied to the end-to-end product manufacturing process for multiple
batches. Introduction of a hold step, referred to as ‘cryopreserve,’ and a ‘select’ step for desired cell types that
maintain phenotype at different stages of the differentiation process alters the key process steps involved in the
development.
There are three main stages in the process. The Master Cell Bank is established at the stage before lineage
commitment. The Master Working Cell Bank is then established from the Master Cell Bank. These two steps are
not the subject of this analysis. Campaigns of cell differentiation to the neural progenitor phenotype are followed
by selection of the preferred cell clones and expansion. This provides cells from which the final product may be
formulated. The question is therefore whether it is better to establish a hold step (marked ‘cryopreserve’ in the
figure) following expansion, or following selection or following differentiation.
As the organization gains knowledge, it can rely more heavily on know-how from this early manufacturing
research but in the early days this will not be possible. The alternative is to proceed to trials with relatively little
process knowledge and to impose a narrow manufacturing protocol. If development is later abandoned due to lack
of efficacy then the financial loss has been minimized.
The tools that were applied
• A New Product Introduction map (NPI map) to provide high-level guidance about characterization and manu-
facturability;
• A Risk Based Approach to identifying the major gaps in process and product quality;
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Figure 2. The ‘development dilemma’ in cell therapy product development. This figure represents two alternative routes of investment
decision in the product development programme. In the process research prioritized route, early investment in process research supports
progression into full process development after clinical trials are proven to be efficacious (A). In the alternative route to prioritize efficacy,
with the provision of a predesigned comparability protocol, further process research has to be conducted after clinical trials are proven to
be efficacious with the potential risk of bridging studies and time delay before full process development for commercial release (B).
CoGS: Cost of goods supplied; PIPS: Provisional in-process specification; PoC: Proof of concept; QTPP: Quality Target Product Profile.
• An Expected Current Value (ECV) method designed to identify the preferred sequence of research investments
that will be needed.
Their interrelationship is shown in Figure 3.
Case study
The process was to manufacture dopaminergic (DA) neurons for clinical use in patients with Parkinson’s disease
(PD).Our study examined three protocols at a stage where they were ready for clinical translation. Themethods were
compared in terms of their readiness for manufacture. The NPI map was used to guide the timing of development
activity, especially the timing of the means of characterization. A risk-based approach prioritized studies that close
gaps in process understanding. At this point ECV calculations were used to manage the ‘development dilemma’.
Parkinson’s disease
PD is a progressive neurodegenerative disease that affects around one percent of the global population by age 65
years. It is currently incurable. The pharmacologic interventions, including L-Dopa, or dopamine agonists help to
manage the disease only in the early stages [4].More invasivemethods, such as deep brain stimulation [5] and lesioning
have been investigated as well. Cell replacement, such as implantation of neural progenitors, is now practical [6].
Transplantation of fetal neuron cells [7] was a revolutionary step and achieved long-lasting improvement in the
condition of some patients [8]. Although the method proved that fetal ventral mesencephalic neurons can survive
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Figure 3. Methodology: inter-relationship of the tools. The decision tool flow chart presented here acts as a high
level decision choice for the implementation of New Product Introduction tool. As detailed in the flow chart, a risk
analysis and resultant acceptable level of risks leads to an expected current value comparison to maximize value and
an improved New Product Introduction map step which leads to product commercialization.
CMC: Chemistry, manufacturing, and control; ECV: Expected current value; NPI: New Product Introduction map.
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Figure 4. Dopaminergic neuron differentiation processes. Major process steps involved in the dopaminergic neuron product
manufacture (A). DA neuron differentiation process diagrams show the three processes described in this article. Process length is
represented by the black line with days of differentiation noted on top of the line (e.g., 21d = day 21 of differentiation). The type of
culture medium and the major differentiation reagents and patterning factors required during the specific stages of differentiation is
shown below the line that indicates process length. Representative DA neuron differentiation developed by Kirkeby et al. (2012) (B),
process developed by Kriks et al. (2011) (C), process developed by Hallett et al. (2015) (D).
DA: Dopaminergic; hESC: Human embryonic stem cell; iPS: Induced pluripotent stem cell.
and integrate, ethical issues and the limited availability of the fetal tissue have driven the search for alternatives.
PSCs from human blastocysts (‘human embryonic stem cells’ or hESCs) provide a potentially unlimited source
of cells with the ability to differentiate into any human cell type [9]. Ethical issues are avoided by using induced
PSCs (iPSCs) [10]. hESCs, when differentiated into neural progenitors, express different neural markers and have
potential neurological function [11]. Recent advances with hESCs and iPSCs under directed differentiation give DA
neuron precursors with the appropriate profile for treatment of PD patients.
Developing CBMPs for PD
In Australia, clinical trials have been conducted using stem cells of parthenogenetic origin [12]. Another clinical
trial is planned by Chinese surgeons using hESCs [13]. Promising claims are being made by researchers in the UK,
Sweden, the USA and Japan using hESC or iPSC cell therapy approaches [14–16].
Malin Parmar and colleagues at Lund University, Sweden, have developed a protocol [17] to generate DA neurons
from hESCs. The resultant cells integrate into the striatum of murine models of PD. The level of differentiation,
integration and disease reversal was comparable to the results from human fetal ventral mesencephalic neurons [18],
the current ‘gold standard’ in cell therapy for PD.
Lorenz Studer’s group at Memorial Sloan–Kettering Cancer Center, USA, has made substantial progress un-
ravelling the molecular mechanisms of PSC differentiation into DA neurons. The Group’s Good Manufacturing
Practice (GMP)-compliant protocol is ready for clinical trials starting either from hESCs or iPSCs [19]. Preclinical
in vivo results in mouse and monkey PD models starting from hESCs or iPSCs show integration and reversal of
disease symptoms [19,20].
Ole Isacson’s group at Harvard University showed that DA neurons from non-human, primate-derived iPSCs,
transplanted into the brain of histocompatible primate PD models integrated and reversed disease conditions [20].
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These three methods were compared to analyse the risks associated with any commercial manufacturing process
based upon them and any consequent product risk to patients.
DA neuron process description
Some key process issues were addressed during early research. These included the replacement of serum with
‘Knockout Serum’ (a chemically-defined, serum-free formulation) and replacement of feeder cell layer with a
coating of extracellular matrix. The planned development was to substitute xeno-free medium components for
animal-derived raw materials. At the time of writing these protocols were not fully compatible with GMP because
the cell lines were maintained on a mouse embryonic fibroblast layer and serum had been used at early stages of cell
line development. A recent report of an hESC line derived under GMP conditions [21] may be the first of its kind.
When the product is to be autologous it is important to apply quantitative methods to qualify the starting material.
Examples are the determination of the level of genetic stability, reliable and repeatable cell counting methods,
determination of viability and quantitative morphological analysis. The following process steps were common to
all three processes:
• A qualitative method of selection of PSCs for differentiation
• Induction of cell starting material into neural progenitors that acquired neural fate
• Directed differentiation into the DA neuroprogenitor stage that can differentiate into DA neuron under terminal
differentiation
• Formulation and, potentially, cryopreservation
• Transportation to the clinic
• Transplantation
Neural progenitor cells or the neuroprogenitor cells are the resultant intermediate stage cell in a directed differentia-
tion process which acquired neural fate. These cells can be differentiated into multiple types of cells with positional
identity under the presence of different patterning factors and their concentrations [17]. DA neuron progenitors are
used for the transplantation.
The overall process length varied significantly between the three processes (Figure 4).
‘Freezing’ the process design
Before process engineers can begin work it is necessary to ‘freeze’ the process. From this point on adjustments must
take place in a controlled manner and records must be subject to version control. A ‘Quality Target Product Profile’
(QTPP) of the product will guide the decision about when the process is ready to be frozen. The correlation between
this and potential efficacy is defined as development proceeds. The pathways for collecting data for the submission
package are less well developed for ATMPs than for pharmaceuticals [22]. Nevertheless, there is a close relationship
between potency assays and overall batch quality and the assays must be identified early in development. Changes
to the impurity profile of a batch may invalidate the method of analysis. Best practice is to develop and validate an
assay in relation to the formulation excipients.
Tool 1: new product introduction map
The NPI process (Figures 5 & 6) is based upon input from various stakeholders. It identifies the prerequisites of
facilities and of product assays. There are critical phase-gates for ‘Stop/Go’ decisions. For robust process design,
the choice of characterization methods should consider more than simply the idea of testing to specification. The
insight so gained will enable identification and control of critical process parameters that affect the Critical Quality
Attributes. During this process the NPI map acts as a framework to acquire, prioritize and organize the growing
body of information. It comprises a logic map (Figure 5) and an approximate sequence of events (Figure 6). It
sets out the interrelationship between the decisions, each of which is then addressed in detail in the Risk-Based
Approach (Tool 2).
Tool 2: risk-based approach
Specific risks must be identified and managed before any clinical use may take place. Nonclinical and clinical data
will be needed to justify any action that is taken to mitigate the risks. The timing and scope of the risk assessments
in Figures 5 & 6 and will vary according to the maturity of the process.
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control strategy and testing strategy with its risk criticality score enables calculation of the residual CQA control risk. An unacceptable risk
level endorses process improvement, redesign and risk reduction actions (indicated with red arrow). The risk assessment is to be
conducted as an iterative process to further assess the risk criticality, when the risk level reaches to an acceptable level development
proceeds to Investigative Medicinal Product Development (indicated with blue arrow). The knowledge gained from preclinical/clinical
studies (B) further assists the process improvement by reduction of risks (black arrows from top pane). This reiterative risk analysis and risk
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CMA: Critical Material Attribute; CPP: Critical Process Parameter; CQA: Critical Quality Attribute; D: Detectability; FMEA: Failure Mode and
Effects Analysis; IMPD: Investigational Medicinal Product Dossier; O: Occurance; MAA: Marketing Authorization Application; QTPP:
Quality Target Product Profile; S: Severity.
We conducted the risk assessment by tabulating the risks by category in relation to the stages of the process (see
Tables 1–3).
To be useful the risks must be amenable to classification and decision making. We applied an open source risk
analysis matrix. The classification of risks is made by combining the likelihood of occurrence with the consequence
for the product or process. Likelihood of the risks was categorized as follows:
Risk probability of occurrence: 1 in 10 = ‘almost certain’; 1 in 100 = ‘likely’; 1 in 1000 = ‘possible’ and so on, in
logarithmic steps to ‘unlikely’ and ‘rare’.
Risk consequences were categorized based on the estimated percentage loss of the total value of the product.
Potential losses were calculated based on the process- and product-dependent risks. ‘Insignificant’ or ‘minor’ risk
categories are 0.001 to 0.01% respectively of total product value and may include very limited reputational
damage. ‘Moderate’ risk, e.g. a risk that product may fail to meet internal standards only, does not have long-term
consequences and involves limited damage to reputation with potential financial loss of about 1% of product
value. ‘Major’ risk involves fatality, permanent disability or emotional injury to limited numbers of patients, lack
future science group www.futuremedicine.com 471
Special Report Sebastian, Hourd, Chandra, Williams & Medcalf
Commercialisation
stages
Explore Progress
candidate
Manufacturing
licence and CTA
Exploit
Clinical trial
Production
Scale
up/out
Regulation Non-clinical
screening
Commerc-
ialisation
starts
Manufacturing
feasibility study
of process
Early process platform
and manufacturing
approaches determined
Pilot GMP
production
facility
Working cell
bank
Qualified
analytical
tests
Basic research &
Pre-clinical model
Cost
analysis
Therapeutic
candidate
determination
Decision to
manufacture
&
to Phase 1
Phase 1
design
‘frozen’
Dose
safety
data
Dose
range
(within phase
1 limits)
Efficacy & 
cost
effectiveness
Safety
&
efficacy
data
Marketing
authorisation
Post
market
approval
dose
CTA
IMP
In vitro & in vivo
assay
development
Product
release
tests Assay improvement
Assay
qualification
and validation
Master cell
bank
Intermediate
cell bank
(lineage directed)
Tender
Process
transfer
Process
improvem-
ent
Pilot
Product
ion
Manufact
uring
Strategy
defined
Qualification
of
equipment
Volume
production
facility
Drug substance
(cell) bank
(differentiated)
Qualification
Development Validation
Production
process
improvement
Scalable
final
process
design
Product
‘fully frozen’
Pre-clinical Phase 1 Phase 2 Phase 3
Approval
and
launch Phase IV
Manufacturing
process
Manufacturing
infrastructure
Cell banking
Process/product
characterisation
Quality
assurance
Phase gates
Characterisation
requirement
Safety Efficacy
Pre-clinicalKey stakeholder attributes
Manufacturer
Regulator
Reimburser
Value realisation
Clinical end points and surrogates, proof of concept
(POC), putative MOA, classification, IMP-CTA Safety in man
Clinical proof of principle,
viable dose
Cost–
effectiveness
Overall equipment
effectiveness,
product repeatability
Pharmacovigilance
Efficacy follow up
CpK, Yield
Efficacy, confirm
therapeutic action
Potency
Cost–
effectiveness
Process efficiency targets,
validation
Dose ranging (toxicology)
Clinical end-points, dose
ranging (pharmacology),
efficacy
CpK prediction
Clinical safety
Potency indication
Sterility, adventitions
agents, cellular
contamination,
tumourigenecity, karyology
Cell number, cost targets, final production scale,
conditions to permit scale-out/comparability
Pharmacological and toxicological safety
In vitro and in vivo models
Pluripotency markers, terminal differentiation markers;
stability (shelf life). Raw material specs, release tests,
critical process parameters, in process controls
Manufacturability and control
Safety
Efficacy
Quality
identity, purity, potency
(function), stability
Cost–effectiveness
Phase 1 Phase 2 Phase 3 Phase 4
Quality Manufacturability Cost effectiveness
Figure 6. Cell-based medicinal product-specific New Product Introduction map. The New Product Introduction map represents high level
product-dependent stages and requirements relevant to specific stages of the product development. The map contains two sections. (A)
shows the steps in development as lists of chevrons. Colors used in this section are for illustrative purpose only. (B) uses color-coded
rectangular boxes (safety, efficacy, quality, manufacturability and cost–effectiveness) to link to the table beneath with hook-shaped tabs
in same color. The dotted vertical line at the boundary of every stage of the preclinical or clinical phases represents a preferred stage gate
at which the necessary product development related to that stage gate need (arranged in the parallel strands) must be complete e.g. a
working cell bank and intermediate product cell bank to be made ready before entering into clinical Phase I. The table shown at the
bottom of the figure in (B) represents the characterization requirements relevant at specific stages of the product development during
preclinical and clinical trial phases.
CTA: Clinical Trial Authorization; GMP: Good Manufacturing Practice; IMP: Investigational medicinal product.
of product efficacy, failure to meet claimed standards, long-term consequences, loss of credibility and reputation,
national press interest and financial loss of 10% of product value. ‘Catastrophic’ risk involves fatalities, disabilities
or emotional injury to many patients, lack of efficacy, major long term consequences, major public or political
concern and financial losses exceeding 25% of total product value.
Risk rating
Based on the likelihood and the consequences, risks were classified into ‘high’, ‘medium’ and ‘low’ categories overall.
The strategy is shown in Table 4. Risk of the product to patients is shown in Table 5. Process-specific risks are
indicated in Table 6. Since the risks in CBMPs for PD mostly fall into ‘high’ or ‘moderate’ assessment categories,
great care must be taken over prevention.
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Table 1. Risks arising from the cellular starting material.
Risk factor Major risks Evidence and mitigation
Starting material
hESCs and iPSCs.
hESC line H9 used commonly in
studies, others including H1, iPSC
lines 2C6 and SeV6
Tumor formation hESCs/iPSCs acquired inherent capacity to form teratoma [23] but fully differentiated cells which lack
the expression of proliferation marker did not result in tumor upon transplantation in mouse
brain [24]
Unwanted
immunogenicity
hESC-derived DA neurons transplanted in rhesus monkey resulted in immunogenicity [25].
Primate-derived iPSC differentiated DA neurons survived in primate brain without any
immunosuppression [26]. Similarly autologous transplantation of primate iPSC-derived DA neurons
survived in primate brain after 2 years without immunosuppression [21,27]
Treatment failure hESC-derived DA neurons transplanted in rhesus monkey resulted in immunogenicity [25]. iPSC
autologous cells immune rejection reported in mouse [28]
Disease transmission Possibility of pathogens in starting material. The current tests only address a limited number of
pathogens. Risk of BSE is a concern
Unwanted tissue
formation
Precision of brain region in final product administration is required to avoid unwanted tissue
formation
Toxicity Only very low risk of toxicity
Cell population heterogeneity
and varied differentiation
capacity
Tumor formation Undifferentiated cells in final product induce tumor [29,30]. Enhanced characterization resolved
tumorigenesis by acute differentiation [19,31]
Unwanted
immunogenicity
Abnormal expression of Hormad1 and Zg16 contributes to immunogenicity of iPSCs [28] so
heterogeneity may contribute
Treatment failure Molecular marker expression of the product is not consistent between different processes. Level of
expression is not quantified
Unwanted tissue
formation
Injection of stem cells into brain may cause inflammation and immune rejection. Risk of other tissue
formation
Growth factors
GDNF, BDNF, Insulin
Tumor formation GFs may induce tumor formation. Similar protocols used in DA neuron derivation and
transplantation without tumors [19,21]
Unwanted
immunogenicity
Possible immune reaction to growth factors
Genetic stability Tumor formation Chromosome aberration results in tumor [32,33]. Level of stability details obtained is not adequate.
G banding or ploidy tests are not sufficient but no clear guidelines on the level of details required
Treatment failure Risk of treatment failure. Risk of other tissue formation
BSE: Bovine spongiform encephalopathy; DA: Dopaminergic; GF: Growth factor; hESC: Human embryonic stem cell; iPSC: Induced pluripotent stem cell.
Table 2. Risks arising from the administration and fate of the product.
Risk factor Major risks Evidence and mitigation
Bio distribution as cell suspension
injected
Treatment failure Bio distribution of injected cells may affect efficacy: Failure to function or survive [34]. Systemic
injection failed to localize to CNS in rodents [35]. DA neuron injection planned for substantia
nigra/striatum in these studies
Host tissue location precision Unwanted
immunogenicity
Transplanted cells were immunogenic [36]
Treatment failure Dyskinesias resulted in human fetal neuron transplantation [37]. Injection location-specific effects
reported (striatum/putamen) [36]. Multiple intra-striatal grafts (better) or single intra-nigral
grafts [38]. Simultaneous striatal and intranigral double injection of nigral cells produced better
efficacy [39]
Cell preparation and devices to
administer drug product (needle
and aggregated DA neuron
progenitors)
Treatment failure Single cells/partial suspension of fetus better [40]. Intrastriatal injection of cells grown on gelatine
microcarrier beads survived [41]
Biological variation of patients
and patient selection
Treatment failure Only few patients had disease reversal in fetal neuron trial [42]
CNS: Central nervous system; DA: Dopaminergic.
Comparability requirements based on identified risks
Post-approval changes to the conditions of manufacture that were described in the Chemical, Manufacturing and
Controls packagemust be addressed adequately. The outcome is heavily influenced by the scope of theComparability
Protocol. A Comparability Protocol is a document describing how a future change to a manufacturing process shall
be managed and the circumstances under which a reduced reporting category for the change may legitimately be
adopted [49]. A ‘bridging study’ is the investigation required to demonstrate that the change has had no significant
impact upon the quality, safety or efficacy of the product.
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Table 3. Risks arising from the correlation of process design, preclinical and clinical studies.
Risk factor Major risks Evidence and mitigation
Extracellular matrix
biological/synthetic
Tumor formation No feeder cells used. Matrigel (may induce tumor [43]). Gelatine, polyornithine, laminin
and fibronectin were used in the process
Unwanted immunogenicity Experimental evidence showed no immunogenicity [19]
Disease transmission Possible
Animal model
6 OH DA model is healthy
compared with
neurodegenerating Parkinson
patients
Treatment failure Models do not fully represent disease condition. Pitx3 ablated (no nigro-striatal
innervation) aphakia mouse model may better represent disease [44]. ES-derived DA
neuron transplantation improves aphakia mouse PD symptoms [45]
Dosage: how much to inject? Treatment failure Fetal neuron transplantation in humans obtained a proportional clinical improvement to
the size of the transplant [46]. 200K DA neurons in mice as a 2-step sequential injection
2 days apart resulted in better efficacy [47]
DA: Dopaminergic; ES: Embryonic stem cell; OH: Hydroxy; PD: Parkinson’s disease.
Table 4. Risk rating categorization table.
Likelihood Consequence Risk rate
Possible Major High
Likely Catastrophic
Almost certain
Possible Moderate Medium
Likely
Almost certain
Unlikely Minor Low
Possible
Table 5. Risk matrix: product risks to patient.
Product dependent risks Tumor
formation
Unwanted
immunogenicity
Treatment
failure
Disease
transmission
Unwanted tissue
formation
Toxicity
Raw material High Medium
Starting material Medium High High
Growth factor Medium
Heterogeneity Medium Medium Medium Medium
Genetic stability High High
Stage of differentiation Medium Medium Medium
Undifferentiated cells in product High High High
Biological variability High
Patient selection (age, sex, etc.) Medium
Bio-distribution Low Low
Tissue location precision Medium High Medium
Cell preparation method Medium Low Medium
Dosage Low Low High
Taken from [48].
For the three processes that we examined, there are several potential changes that may become necessary before
human application at commercial scale:
• Changes in starting materials
• Changes in the raw materials
• Replacement of a growth factor
• Changes in grade of cell culture plastics
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Table 6. Risk matrix: process-related risks.
Process related risks Potential risk Risk level
Cell line variability and need for new cell line High input biological variation to process. Comparability issue if
new cell line used
High
Facility (cell line derivation) qualification qualification/validation Quality risk Medium
Process length (∼25 days) Control of process, financial risks when batch fails Medium
Critical dose and temporal dependency of growth factors/agents Risk to control process and growth factor batch variability Medium
Risky process steps
• Embryoid body
• Passaging
Heterogeneity, process control, scale issues High
Specification of surrogate marker expression Lack of relevance to potency and unknown risk of variation Medium
Lacks intermediate stage characterization Process control risk, financial risks when batch fails Medium
Lack of intermediate banking or cryopreservation Process control, financial risks when batch fails High
Drug product formulation Not addressed at all, substantial changes may occur High
Transportation and stability Not sufficiently addressed, may affect product stability Low
Drug-delivery system/method Precise tissue location and tissue damage, IP issues High
Dose Treatment failure, dyskinesia, unwanted tissue formation High
IP: Immunoprecipitation.
Taken from [48].
• The research lines may carry risks from (unproven) transmissible spongiform encephalopathy content and, unless
the banks carry satisfactory details about provenance of cell isolates and all medium components, it will become
appropriate to rebuild them
• Reprogramming methods can influence the cell quality even when genomic stability and the passage number of
the cell line used are held constant
• Manufacturing process may change with improved technology
• Drug Product formulation may vary
• The current processes lacks a cryopreservation step and such a step is likely to be needed for an allogeneic product
• Manufacturing location may change
• Local regulations may affect the operability of the process
ACritical Quality Attribute (CQA) is a property, feature or characteristic of the final product thatmust be conserved
by maintaining process controls within acceptable limits. At present there is a discrepancy in the marker-based
CQAs between the processes (see Table 7), reflecting the historical path of research at each site. The measurement
method of each of those CQAs is currently qualitative and when we began our work none of the studies to date had
addressed quantitatively the effect of variability in the expression levels. In-process measurement of these CQAs
therefore warrants early and major investment to assist process control later on. The CQAs mainly indicate the
product purity but the profile of impurity and the impact upon efficacy of variation of both purity and impurity
profile has to be addressed. A specification must be set on both parameters.
Process length and provenance and security of supply of raw materials are also important early considerations
as they can significantly contribute to the process robustness and to the cost of goods. Steps to reduce risks in this
area must be considered early in the product development.
In-process measurement offers the potential for real-time release of drug product and must be developed
alongside the process if it is to be effective. The strategy for cell banking must be considered during late preclinical
development and the size of the banks must be designed in order comfortably to maintain the QTPP. In the research
stage processes, cells were differentiated into progenitors and then transplanted into disease models. In any process
to deliver cryopreserved drug product this must be augmented with controlled cryopreservation and thaw steps.
The viability post-thaw needs to be adequately reproducible.
Tool 3: ECV-based prioritization
The risk analysis of the differentiation processes identified several key gaps in characterization, process and product
knowledge. Any decision to mitigate these gaps requires investment of time and money. The management of
intra-project investment resembles the management of a multi-project research portfolio with the difference that
study options rather than product options are examined. A decision to make such investment early in the product
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Table 7. Surrogate markers of quality used in three processes described in this study. The specific molecular marker
expression quality (second to fourth columns) is representative as the measurement system used was not a quantitative
method (indicated in the last column).
Surrogate markers In vitro expression profile from studies Method of detection
Kriks Kirkeby Hallett
DA release +ve +ve – Amperometry, HPLC
qPCR, immunodetection
TH+ 75% +ve 7%
Girk2 +ve (5%) +ve +ve
DAT +ve (5%) – –
EN1 – +ve +ve
FOXA2 80 +ve 20%
LMX1 65 +ve –
-tubulin – – +ve
CORIN – +ve –
Nurr1 55 – –
OTX2 80% – +ve
TH+/ FOXA2+ 20% – 2%
LMX1+/FOXA2+ 90% 80% –
Purity/negative markers
5HT (serotonergic) 2–3% – 1–2%
GABA 5% – –
Proliferation
PCNA
Ki67
1% Progressive reduction
Names shown in the second row indicate respective processes developed by the researchers detailed in Figure 4.
’–’ indicates no data available for the particular marker for that particular process.
DA: Dopaminergic; HPLC: High-performance liquid chromatography; PCNA: Proliferating cell nuclear antigen; qPCR: Quantitative real time polymerase chain reaction.
development lifecycle improves market readiness and commercial viability later on. A quantitative tool is needed
and an under-exploited method, normally used for R&D portfolio management can usefully be applied.
ECV decision tool
In what follows we examine decision optimization in the given project. Resources are limited; research challenges
seldom are. How do we choose which studies to do and when? Strategic choices must be made about how best to
deploy R&D expenditure. However, we may feel good because the projects are progressing well, but ‘doing projects
right’ is not the same thing as ‘doing the right projects’ [50] and our feelings may be misleading us. Humans are
notoriously poor at making decisions based on anything other than the simplest probabilistic concepts [51]. By
making use of the technique below we can use the maximization of value at any given present moment to make
decisions about priority of research for a process in development.
ECV-based tools have been long-established for the management of R&D portfolios. Similar methods can
be applied in CBMP process research projects because they allow us to balance the investment decisions in the
‘development dilemma’.
Key concepts
‘Time-related uncertainty’: Any investment becomes less speculative as uncertainty is reduced. The art is therefore
to balance the degree of speculative investment against the progressive removal of uncertainty to establish an
acceptable trade-off.
‘Net Present Value’ (NPV): Here the NPV is the value now of a project that will be delivered at some future time.
We normalise the time-related value to a common point so that the effects of risk and inflation are removed. The
decision usually must be made now, so the present is chosen. An NPV is the payoff discounted to the present using
a factor that reflects inflation and the risk-related diminution of value to give a Discounted Cash Flow (DCF). It
lumps together the risk factors into one global term. DCF should be used, strictly, only to value assets. An ‘options’
approach is more suitable for the decision trees typically found in project plans. We can develop this using:
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ECV: The ECV is the expression of the commercial worth of a project or option in the present day and adjusts
for risk at a detailed level. It often involves a decision-tree analysis, compounding the effect of risks.
An ECV is commonly used to prioritize projects in a portfolio. The ranking by value is compared with the
available resources and a line-draw provides a threshold below which projects are de-selected.
The conventional expression of the ECV is [52]:
ECV = (NPV × PCS − C ) × PTS − D (Eq. 1)
The conventional expression of risk-based ECV, based upon the cost of commercialization and the cost of devel-
opment, each adjusted for their own respective probability or risk
Where:
C = Cost of commercialization or launch
D = Cost of development
ECV = Expected current calue
NPV = Net present value
PCS = Probability of commercial success
PTS = Probability of technical success
We can manage the research using simple risk models based upon the project plan. This approach takes as its
tenets the ideas that each study allows a decision to be made. We can represent the outcome of each activity as a
milestone with a probability-weighted outcome as a decision point. The possible outcomes at any one time may
then be calculated as a cumulative probability across the paths that determine that decision tree. Each time a study
is concluded the calculation is repeated. This technique shows the progressive increase in the value of the project(s)
over time. The gradient of maximum rate of value increase can be used to prioritize research decisions and may be
modified by strategic or political issues.
This tool was developed by the research management theorist F Peter Boer [53]. Boer’s insight brings an important
perspective to what had formerly been an art by assigning value to the option to abandon i.e. it includes the
‘opportunity cost’ of a course of action in the calculation. Competitive advantage will vest in researchers who collect
information from past projects that allows them the most accurate predictive skill.
The concept is relevant to CBMPs at their current stage of process knowledge because of the relative absence of
information on the process capability at each step. An organization that builds a re-usable library of such data will
gradually be able to rely more on rules of thumb than this more model-based approach.
The value of the approach is best considered by applying it in the context of an illustration from the Project. In
Figure 2 there is a choice: whether to prioritize research on the efficacy or research on the manufacturing route. We
can represent this choice with some very broad scoping estimates as shown in Figure 7.
The possibility that either the manufacturing research or the in vivo work may lead to project failure represents a
‘unique risk’ for the project; that is to say, it is a risk inherent in the work and does not rely on external influences.
In order to make a decision with confidence based solely on the unique risk it is best to quantify the cumulative
risk for each of the alternative courses of action. The decision points can be represented using a ‘Decision Tree’, in
effect a quantitatively-loaded version of Figure 2.
By contrast, the quantification of the costs of the research choices and their prioritization can be done using a
‘Real Options’ approach [54,55]. This is based on the observation that the future decision whether or not to invest at
a decision point depends on the discounted value of the project at that time weighed against the cost to reach that
point. This approach has traditionally been divorced from the Decision Tree method because it is calculated using
‘market risk’ i.e. risk that, unlike ‘unique risk’, cannot be mitigated by diversification. However, as Boer points
out [53] the combination is possible and legitimate because project plans represent, in effect, a series of options with
the ability to proceed or to withdraw at each phase.
Following Boer’s description the approach can be depicted as a series of steps that are illustrated here for our
example. In these illustrations the costs given and the value to be realized are hypothetical. This is for two reasons.
Firstly the instances of cost and value for a PD product are commercially-sensitive data. Secondly the values used
are to make the decision points clear in a way that would be obscured by a calculation with many more layers and
more nuanced costs.
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Yes
Yes
$ECV Development $
(D)
No
Commercial failure
Technical failure
No
Commercial success (PCS)
Technical success (PTS) Launch $
(C)
Figure 7. Expected current value decision tool. The ECV is based on the probability of technical success and the
probability of commercial success assuming that the product can be launched.
C: Cost of commercialization or launch; D: Cost of development; ECV: Expected current value; PCS: Probability of
commercial success; PTS: Probability of technical success.
Case 1: prioritize efficacy
Step 1: organizing the calculation
Three inputs are needed: the risk-free interest rate and the cost of capital (the discount rate) are represented for
convenience here by the values of 5% and 12% as in Boer’s published work. The third input, the ‘volatility’ in
the market influence, is needed to deal with the options part of the model and this aspect can preferably be
regarded as the ‘volatility of the cash margin of the product to which the business plan is linked’ [53]. This will be
familiar to researchers in advanced therapy manufacture as the margin arising from the uncertainty surrounding
the reimbursement model versus the uncertainty in the cost of goods calculation.
For simplicity let us assume that, on completion of the process research, the deployment of the technology to
the launch site will cost $3 million. The present value of the project is shown by the sum of the NPV and the initial
investment.
In practice if an organization were to follow the approach in our example then a prudent course of action would
be to perform sensitivity calculations on the result in order to show the extent to which the outcome is influenced
by small changes in the basic assumptions.
The NPV is referred to the beginning of the commercialization phase. However, to regard the commitment of all
research costs as a single figure is to disregard the value of the ability to abandon the project if required at appropriate
phase-gates, thus saving further commitment. This is where the Decision-Tree calculation comes into play.
Each phase of the project comprises a series of activities. The duration, probability of success and discounted
cost of each activity up to launch are placed in a simple spreadsheet-based model. In the example of Figure 2 we
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see two main activities (process research and in vivo trials) and two other activities (develop comparability protocol
and conduct bridging studies) that are associated with pursuing the in vivo study as a priority.
The probability of success is estimated and the confidence of the estimate will improve to an extent over time as
the organization encounters similar steps in successive projects.
In our illustration (greatly simplified from the real case) there is an assigned NPV of $3 million upon launch.
This is realized in year 4 if the in vivo trials (efficacy) are prioritized.
Step 2: calculation
Decision-tree only approach
The valuation, making use of the cost of abandonment, is calculated as the sum of the probability-weighted value
and cost of each branch of the Decision Tree. For the case where efficacy is prioritized the result is:
=
∑
Value s × Pr obabil i ti e s (Eq. 2)
Calculation of the probability-weighted value of each branch of the Decision Tree is based upon the cumulative
costs for that branch adjusted using the cumulative probability of success for that branch. Each branch represents
a possible outcome of the process development stage.
= (Risk − adjusted value of arm to exploitation)
−(Cost of abandonment at year 4)
−(Cost of abandonment at year 3)
= $86, 038 − $199, 945 − $310, 1268 = ($424, 174)
Note that failure to include the option to abandon gives a valuation of
= $285, 983 − $1, 332, 965 = ($1, 046, 982)
The result, in this case, is not attractive either with, or without, the option to abandon although the exclusion of
the option to abandon results in a far less attractive value.
Decision-tree & real option approach
The ‘market risk’ can now be factored in i.e. the uncertainty that arises from features of the market opportunity
and our limited knowledge of it.
This alternative viewpoint consists of framing the project as a series of investment decisions, one at each decision
point. To derive a quantitative comparison we must work back from realization of value at launch to the present
moment, using the project value subsequent to each point as the value that may be realized by exercising the
decision or ‘option’ that precedes it.
The decision at year 4 to deploy to launch is a ‘real option’ to invest $3million (the ‘exercise price’ or ‘strike price’)
in addition to the value of the successful project, i.e. the present value, at the time of the decision, or ‘underlying
security’ (the ‘stock price’) for the option. Using the DCF method this is:
DCF =
Investment at decision point
Discount factor (Years to decision)
+ Value release (Eq. 3)
Discounted Cash Flow can be used to express the balance of value at the present time of a decision to pursue a
positive course of action at each decision point in the Decision Tree.
=
$3M
(1.05)4
+ $1.907M = $4.375M
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In order to include the impact of volatility, the value of this option over the year 3–4 is calculated using the
Black-Scholes model at a market volatility of 50%. The basis of the calculation and user-friendly tools to calculate
it are widely available. Here we use a popular online tool [56] to give $2.011 M. Adjusted for the probability of
success (50% of this arm) the value of the option becomes $1.006 million.
The value of $1.006 million is the underlying security or ‘stock price’ for the first decision point. We can now
work back to that previous decision point which is the call option at the end of year 2 to spend $1.250 million on
process research in years 3 and 4, by using a strike price for the option equal to the cost of the next stage or research
investment discounted to that decision point at the risk-carrying rate (as experimental work is involved) of 12%.
=
$500k
(1.12)3
+ $750k
(1.12)2
= $953k
The Black-Scholes calculation returns $336 k and, allowing for a 30% probability of success at this decision point,
the value becomes $101 k. The discounted cost of reaching this point is the sum of the first two years of research
($443,240) so the project as a whole has a negative value ($342 k; Figure 8).
Case 2: prioritize process
We now turn our attention to the alternative, which is to place more confidence in a positive outcome to the
efficacy studies and to absorb early the costs of process development work instead. This is not a straightforward
comparison because the cost of performing comparability studies is largely removed. In the real case there will still
be work to do on the comparability protocol but in our example we simplify by omitting it. We continue with the
same values for the risk-free interest rate, the cost of capital and the ‘volatility’.
Year 1 Year 2 Year 3 Year 4
Proceed 30%
100%
Abandon 70%
Proceed 50%
Abandon 50%
Conduct process
research
Conduct in vivo trials
Conduct bridging
studies
Cost – $750,000
DCF – $533,835
Cost – $500,000
DCF – $398,597
Cost – $50,000
DCF – $44,643
Discount rate 12%
per annum
Develop
comparability
protocol
Cost – $500,000
DCF – $355,890
Ps (Cu) 15%
Vs (Cu) $573,589
NPV $3,000,000
DCF $1,906,554
Pf (Cu) 15%
Cf (Cu) $1,332,965
Pf (Cu) 70%
Cf (Cu) $433,240
Cost of
abandonment
$199,944.77
Cost of
abandonment
$310,267.86
Risk adjusted
value of this arm
$86,038.37
Rolling out regardless
Return of rolling out regardless $285,983.14
Cost of rolling out regardless $1,332,965
Expectation -$1,046,981.97
Return overall (risk adjusted)
-$424,174.25
By opting to abandon
100% – Total probability of outcome
Figure 8. Expected current value calculation based on ‘Prioritize efficacy’ route. The Figure illustrates the steps involved in the ECV
calculation at an annual discount rate of 12%. A representative time frame required for the development is shown in the top panel
indicated in years. A well-designed comparability protocol is a critical prerequisite in this route of development. Dependent on the data
available from in vivo studies, a choice can be made to abandon the development (70% probability) or to proceed with further process
development and bridging studies (30% probability in this case). At the later stage of the development a further 50% probability exists
for failure. This adds to the early-stage abandonment probability of 70% and results in a cumulative 85% probability for failure.
Cf: Cost to failure; ‘Cu’: Cumulative; DCF: Discounted cash flow; NPV: Net present value; Pf: Probability of failure; Ps: Probability of success;
Vs: Value if successful.
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Decision-tree only approach
=
∑
Value s × Pr obabil i ti e s (Eq. 4)
Calculation of the probability-weighted value of each branch of the Decision Tree.
= (Risk − adjusted value of arm to exploitation)
− (Cost of abandonment at year 3)
= $320, 130 − $747, 768 = ($427, 638)
Note that failure to include the option to abandon gives a different level of valuation than in the first case. This is
due to the smaller influence of avoiding incurred development costs for the whole project than is the case above.
= $640, 602 − $1, 068, 240 = ($427, 638)
Once more the result is not attractive either with, or without, the option to abandon.
Decision-tree & real option approach
The decision to deploy at year 3 is valued at (with reference to Equation 3):
=
$3M
(1.05)3
+ $2, 135M = $4.727M (Eq. 5)
Calculation of the value of launch taking into account the discounted investment and the discounted value released.
Note that each component bears a different discount factor.
The value of this option over the year 2–3 is once more calculated using the Black-Scholes model at a market
volatility of 50% and a cost to exercise (the launch cost) of $3 million. The decision to launch is here only one year
from the previous decision. Here the model returns a value of $2.020 million which, adjusted for the probability
of success (30% of this arm) becomes $0.606 million.
In this case there is no previous decision point and the discounted cost of reaching this decision point is the sum
of the first two years of research ($1,068,240) so the project as a whole has a negative value ($462,240) Figure 9.
Discussion
The ‘development dilemma’ in CBMP process design illustrates the importance of a systematic approach to
management of risk, investment and sequence of studies for an area where the body of process knowledge is
not as extensive as it is in, say, pharmaceutical chemical engineering. Product complexity means that improved
characterization of the product and intermediates is valuable. This comes at the expense of time and money. The
tools illustrated here gave guidance to the UKRMP Team in terms of area of research focus and prioritization of
topics. The NPI map emphasizes development and characterization requirements relevant to the each stage of the
process development (i.e., when to do the work). This tool, in combination with the risk assessment, identified
existing gaps in product knowledge (i.e., what work to do). Net commercial value generation of such development
can be assessed with ECV method presented (i.e., whether to do the work and in what order).
In this example, genetic stability and tumorigenesis, the development of an intermediate-stage product and
formulation are the key areas for further research.
Genetic stability & tumorigenesis
Studies show that different culture conditions affect the genetic stability of hESCs and the exact causes may be hard
to identify. Significant advances have been made in the maintenance of stem cells in culture with replacement of
animal-derived feeder cell layers and the replacement of serumwith definedmedium. Even with such improvements,
stem cell culture practice still suffers from incidences of karyotype abnormality in culture [57]. Advanced analytical
techniques show that enzymatic passaging and nonfeeder matrices may affect the karyotype and gene expression
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Year 1 Year 2
Conduct process
research
Cost – $750,000
DCF – $669,643
Cost – $500,000
DCF – $398,597
Abandon 70%
Rolling out regardless
Return of rolling out regardless $640,602
Cost of rolling out regardless $1,068,240
Expectation -$427,638
Return overall (risk adjusted)
-$427,638
By opting to abandon
Pf (Cu) 70%
Cf (Cu) $1,068,240
Cost of
abandonment
$747,767.86
Discount rate 12%
per annum
100%
Conduct in vivo trials
Year 3
Ps (Cu) 30%
Vs (Cu) $1,067,101
NPV $3,000,000
DCF $2,135,341
Risk-adjusted
value of this arm
$320,130.28
Proceed 30%
100% – Total probability of outcome
Figure 9. Expected current value calculation based on ‘Prioritize process’ route. This figure illustrates the expected current value
calculation method when the process-prioritized route is chosen. Early process research followed by in vivo studies generates a 30%
probability to proceed with the development and a 70% probability to abandon further development. Significant increase in the
cumulative value ($1,067,101) is obtained in this route.
Cf: Cost to failure; ‘Cu’: Cumulative; DCF: Discounted Cash Flow; NPV: Net Present Value; Pf: Probability of failure; Ps: Probability of
success; Vs: Value if successful.
profile of stem cells [58]. Such culture conditions were reported to have deleterious effects on chromosome stability
and copy number variation within five passages [59]. Other studies found no difference between enzymatic and
mechanical passaging [60]. Recent work from the iPSC-based trial for age-related macular dystrophy at the RIKEN
institute came to a halt due to potentially carcinogenic mutations [61]. hESC-derived neural progenitor cells
injected into rat brain resulted in PSCs remaining and also caused teratocarcinoma-related premature death in
some animals [29]. A patient injected with neural stem cells was reported to form brain tumor after a few years
of treatment [62]. From a screen of 140 independent hESC lines, the extent of the mutations in the TP53 gene
that potentially cause cancer was revealed [63]. Different types of mutations and genetic changes to the cell lines
make them more susceptible to develop cancer [64]. The expansion and differentiation process is not standardized
in the protocols in our study and they are subject to high levels of operator discretion. As the evidence suggests that
the presence of genetically unstable cells may cause tumors [65] it is appropriate to include studies to identify and
control physicochemical features of the culture conditions that affect genetic stability and resultant tumorigenesis.
Hold steps
The process of DA differentiation is longer than that presented in Figure 4 as the initial expansion of hESCs prior
to differentiation is not represented. From a thawed hESC vial it may take several passages to obtain a culture
with stable growth rate (unpublished data). Taking into consideration the duration of initial expansion the whole
process may exceed six weeks. From a GMP perspective this is challenging to manage and the introduction of a hold
step would reduce the risk considerably. As indicated in Figure 1, introduction of a cryopreservation step would
facilitate the process. Cryopreservation of neural progenitors with capacity to differentiate into GABAergic neurons
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has been shown to maintain viability and differentiation potential [66]. Although not identical to the manufacture
of neural progenitor cells [67], this study suggests that a population of neural precursor cells can be generated and
maintained for several passages before differentiating into DA neurons [68].
Formulation
In the preclinical studies described in this article, drug substance (differentiated DA progenitor neurons) was
suspended in cell culture media or PBS [19,45,46] or in HBBS prior to transplantation [69]. Inclusion of a cry-
opreservation and thawing step for the formulated drug product would allow the distribution of drug product
manufactured centrally to the point of administration. Some studies have examined ways of cryopreserving neural
progenitors without compromising quality. Mouse neural progenitors cryopreserved in differentiation medium
with 10% DMSO maintained viability and differentiation potential [70]. A recent study using mouse DA neurons
cryopreserved in DMSO- or glycerol-containing agent showed that these did not adversely affect the quality of the
cells [71]. Another study proved that cryopreservation of human iPSC-derived DA neurons did not adversely affect
product quality. Cryopreserved cells maintained high viability and molecular marker expression profiles compared
with non-cryopreserved cells [72].
The principles described in this paper may be extended, with care, to other categories of pluripotent stem cell
therapies. Two examples will illustrate this point.
iPSC-derived cardiomyocytes [73] as an autologous cell source for myocardial repair also require robust preclinical
and clinical evidence in order to provide a safe and reproducible product. Just as for PD treatment the product
will require a uniform cell sub-type that is free from tumorigenic cell contaminants. In this case it is especially
important that the cell functionality, survival post-engraftment and behavior as an adult cell are adequate. The
intrinsic variability of the source material for what is likely to be an autologous therapy, is an additional and
somewhat different hurdle and would require a carefully-justified qualification of prospective patients in addition
to the considerations for PD in order to avoid straying beyond the parameters that are accommodated in the control
strategy.
By contrast iPSC-derived cells for use in conditions such as degradation of diarthrodial joints by arthritis may,
in the case of hyaline cartilage at least, be feasible from an allogeneic cell bank but in this case the design of the
process may progress through mesenchymal stem cell banks as therapeutic intermediates in order to avoid the
heterogeneity that will otherwise attend attempts to differentiate directly to, for example, chondroprogenitors of
predictable efficacy [74].
Conclusion
The research and investment needed to produce safe, economic, reproducible and operable manufacturing processes
for novel cell-based therapies is significant. The research community has found its own, often local, methods for
addressing priority for studies and for making decisions about when and how to address the features of the process
that exert the most influence over product properties.
We offer a set of three interrelated tools that have found value in the UK Regenerative Medicine Platform
project where we have applied them to the process design for neuroprogenitors. As the research community adds
to its knowledge base we look forward to a time when the insights gained will permit faster and more accurate
planning and execution of process studies based upon increasing levels of confidence in estimation of time, cost
and probability of success of process design studies.
The overarching priority for the sector is the generation of succinct, effective, capable processes. Using the
approach described above the research team was able to reduce the considerable detail within the existing protocols
to a concise process manufacturing instruction that captured the constraints that were necessary to manage the
process features that exert the most influence. The key attribute of effective technology transfer documents between
sites, personnel and programmes is, in our experience, this brevity and focus. Its achievement requires a systematic
and robust methodology that focuses time and resource on a hierarchy of research priorities.
Future perspective
It is a commonplace observation in the development of medicinal products that the first entrant to market for a
treatment obtains 80% of the market share or better and that this dominant position is difficult for later entrants
to displace. As a result the race to shorten development times and to maximize the value of the resources deployed
is a deciding factor in commercial success. We expect two main trends to emerge in the development of cell-based
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therapies over the next 5–10 years. Both relate to the avoidance of unnecessary use of time and money. The first
relates to scaling up and is the reduction in the rate of attrition of candidate products between discovery and launch.
In order for an organization to have confidence in its pipeline of candidates and to minimize the number that are
abandoned in development there must be an accurate reflection of the ‘at launch’ process and supply chain during
the proof of concept studies. Without this insight there is a risk that unforeseen constraints during manufacture
at large scale will cause the process features that exert the most influence over product properties to impact on the
efficacy and safety of the product, causing a loss of comparability. In order to reduce this risk to an acceptable
minimum there must be a growing insight, and preferably a library of studies of the relevant process unit steps,
that will enable the process engineers to focus on the features most likely to exert that influence. The second trend
applies to those processes that are best scaled out i.e. performed in multiple parallel batches at small scale. Here it
will be important to map, characterize and design out the process features that introduce unwanted variation in
the control strategy. These features may be human, instrumental or environmental. Full automation may be an
unsustainable cost for these largely manual processes and we expect to see the emergence of ergonomically-designed
mechanical aids to processing that assist reproducible manipulation through control of timing, materials handling
and dispensing and temperature. This trend to mechanization, similarly to the characterization of the unit steps in
scaling up, will inform the work of the inventing biologists, becoming part of the vocabulary and sometimes the
bench equipment, of the front-end scientists.
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Executive summary
• In order to ensure market launch as quickly as possible and with judicious outlay, the process developer must
reconcile two opposing needs. To ensure comparability of manufacturing process at commercial scale there must
be manufacturing research sufficient to satisfy the ‘Chemical, Manufacturing and Control’ section of the
regulatory application dossier. This must occur at a stage in the project cycle early enough to avoid unnecessary
process re-engineering late in development. However, by no means all candidate products succeed at clinical trial
and it is desirable to avoid spending money unnecessarily on process research for these putative products. The
dilemma can be addressed through the careful use of three decision-making tools. The tools are illustrated in this
paper using a case study of a treatment for Parkinson’s disease.
The tools that were applied
Tool 1: new product introduction map
• The tool allows the examination of the decision points in the context of the overall product development.
Tool 2: risk-based approach
• A development of the normal requirement for product and process risk analysis, this tool identifies the topics
that warrant focused attention.
Tool 3: expected current value-based prioritization
• A project-specific modification of a portfolio-balancing tool, this tool allows decisions about timing of
investment to be made on a quantitative basis.
Case study: Parkinson’s disease
• Parkinson’s disease (PD) is a debilitating condition that is costly to manage and control. It is of growing
importance as the average age of citizens in the developed world increases.
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• The characteristics of a cell-based therapeutic product candidate for PD are discussed in the context of a specific
project within the UK Regenerative Medicine Platform programme.
Dopaminergic neuron process description
• The overall process is described and the challenges are described that arise from the need to ‘freeze’ the process
as early as possible in a form in which the product can be made at scale to a predictable and acceptable
specification. Two situations are used to show how a value-based development decision may be made: one based
upon prioritizing early evidence of efficacy and the other based upon prioritizing the early evidence of process
capability.
Discussion
• The application of the tools described in this paper is considered in the context of management of risks to the
patient that will otherwise arise. The potential for realization of the risks is illustrated with reference to the
known behavior of embryonic and induced pluripotent stem cells.
Conclusion
• The importance of brevity and focus in process development for advanced therapies is re-emphasized and the
application of the tools described is placed in that context.
Future prospects
• The future of cell therapy manufacture is likely to be divided between products that require up- or out-scaling
for manufacture. Robust process characterization is essential for both yet the features of the process that are
relevant may differ between the two categories. Both need systematic assessment. Over time, a growing
familiarity with effective techniques for focused process research coupled with a growing library of case studies
will empower the user community.
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